

Provider Bulletin

April 2023

New specialty pharmacy medical step therapy requirements

Effective for dates of service on and after July 7, 2023, the following specialty pharmacy codes from current or new *Clinical Criteria* documents will be included in our existing specialty pharmacy medical step therapy review process. Step therapy review will apply upon prior authorization initiation or renewal in addition to the current medical necessity review of all drugs noted below.

The list of *Clinical Criteria* is publicly available on our provider website. Visit the *Clinical Criteria* website to search for specific *Clinical Criteria*.

Clinical Criteria	Status	Drug(s)	HCPCS codes
ING-CC-0002	Preferred	Zarxio	Q5101
ING-CC-0002	Non-Preferred	Granix	J1447
ING-CC-0002	Non-Preferred	Neupogen	J1442
ING-CC-0002	Non-Preferred	Nivestym	Q5110
ING-CC-0002	Non-Preferred	Releuko*	Q5125

* Releuko is being added to the existing Step Therapy for Short Acting Colony Stimulating Factor Agents; all other drug statuses remain the same.

Email is the quickest and most direct way to receive important information from Anthem Blue Cross.

To start receiving email from us (including some sent in lieu of fax or mail), submit your information using the QR code to the right or via our online form (https://bit.ly/3lLgko8).



https://providers.anthem.com/ca

Anthem Blue Cross is the trade name of Blue Cross of California. Anthem Blue Cross and Blue Cross of California Partnership Plan, Inc. are independent licensees of the Blue Cross Association. Anthem is a registered trademark of Anthem Insurance Companies, Inc. Blue Cross of California is contracted with L.A. Care Health Plan to provide Medi-Cal Managed Care services in Los Angeles County. CABC-CD-012852-22-CPN12278 April 2023